Arthur Kuan, CG Oncology CEO
January 24, 2024 09:00 PM ESTUpdated 06:40 AM
Financing

Biotech's 2024 IPO sea­son kicks off with heavy de­mand for CG On­col­o­gy in $380M list­ing

Kyle LaHucik

Senior Reporter

NEW YORK — Blad­der can­cer drug­mak­er CG On­col­o­gy will de­but on the Nas­daq Thurs­day morn­ing in what is ex­pect­ed to be the first of at least …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times